Navigation Links
Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
Date:1/29/2009

NEW ROCHELLE, N.Y., Jan. 29 /PRNewswire/ -- Two common strains of methicillin-resistant Staphylococcus aureus, commonly known as MRSA, were virtually eradicated in the laboratory by exposing them to a wavelength of blue light, in a process called photo-irradiation that is described in a paper published online ahead of print in Photomedicine and Laser Surgery. The article will appear in the April 2009 issue (Volume 27, Number 2) of the peer-reviewed journal published by Mary Ann Liebert, Inc. The paper is available free online at www.liebertpub.com/pho

Antibiotic-resistant bacterial infections represent an important and increasing public health threat. At present, fewer than 5% of staphylococcal strains are susceptible to penicillin, while approximately 40%-50% of Staph aureus isolated have developed resistance to newer semisynthetic antibiotics such as methicillin as well.

Chukuka S. Enwemeka, Deborah Williams, Sombiri K. Enwemeka, Steve Hollosi, and David Yens from the New York Institute of Technology (Old Westbury, NY) had previously demonstrated that photo-irradiation using 405-nm light destroys MRSA strains grown in culture. In the current study, "Blue 470-nm Light Kills Methicillin-Resistant Staphylococcus aureus (MRSA) in Vitro," the authors exposed bacterial colonies of MRSA to various doses of 470-nm light, which emits no UV radiation.

The two MRSA populations studied--the US-300 strain of CA-MRSA and the IS-853 strain of HA-MRSA--represent prominent community-acquired and hospital-acquired strains, respectively.

The authors report that the higher the dose of 470-nm blue light, the more bacteria were killed. High-dose photo-irradiation was able to destroy 90.4% of the US-300 colonies and the IS-853 colonies. The effectiveness of blue light in vitro suggests that it should also be effective in human cases of MRSA infection, and particularly in cutaneous and subcutaneous infections.

"It is inspiring that an inexpensive naturally visible wavelength of light can eradicate two common strains of MRSA. Developing strategies that are capable of destroying MRSA, using mechanisms that would not lead to further antibiotic resistance, is timely and important for us and our patients," says Chukuka S. Enwemeka, PhD, FACSM, Co-Editor-in-Chief of the Journal and first author of the study.

Photomedicine and Laser Surgery is an authoritative peer-reviewed journal published bimonthly in print and online. The Journal provides rapid publication of cutting-edge techniques and research in phototherapy, low level laser therapy (LLLT), and laser medicine and surgery. Reports cover a range of basic and clinical research and procedures in medicine, surgery, and dentistry; they focus on safety issues, new instrumentation, optical diagnostics and activities related to the understanding and applications of biophotonics in medicine. Photomedicine and Laser Surgery is the official journal of the World Association for Laser Therapy (WALT), North American Association for Laser Therapy (NAALT), and International Musculoskeletal Laser Society. Tables of contents and a free sample issue may be viewed online at www.liebertpub.com/pho

Mary Ann Liebert, Inc. (www.liebertpub.com), is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Laparoendoscopic & Advanced Surgical Techniques and Journal of Gynecologic Surgery. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available at www.liebertpub.com

    Mary Ann Liebert, Inc.  140 Huguenot St., New Rochelle, NY 10801-5215
    www.liebertpub.com  Phone: (914) 740-2100  (800) M-LIEBERT
    Fax: (914) 740-2101

Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext. 2156, vcohn@liebertpub.com


'/>"/>
SOURCE Mary Ann Liebert, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
2. New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
3. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
4. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
5. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
6. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
7. Opportunities to Highlight Type 1 Diabetes in November
8. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
9. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
10. New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery
11. Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):